Identification of safety biomarkers evaluated against AMPK inhibitors

✓ A drug metabolism and pharmacokinetic group in a clinical research institute are working on safety and toxicity biomarkers against AMPK inhibitors

✓ Once the biomarkers have been identified, they intend to filter out best biomarkers to be included in their interventional clinical trial of new AMPK inhibitor

✓ The shortlisted safety biomarkers are expected to be measured in the clinical trial to determine dose-concentration-effect relationship
A search in GOBIOM database by keyword ‘AMPK’ in ‘Target Name’, keyword “Safety” in ‘Application’ retrieves all the safety biomarkers reported against AMPK inhibitors.
Results aid in identification of relevant safety biomarkers to

✓ Better understand early toxicity in animal studies
✓ Aid in initial dose selection in clinical studies
✓ Improve safety monitoring in phase 1 and 2 clinical trials
A search in GOBIOM database by keyword ‘AMPK’ in ‘Target Name’ and keyword “Pharmacokinetic” in ‘Application’ retrieves all the pharmacokinetic biomarkers reported against AMPK inhibitors.
Results aid in identification of relevant pharmacokinetic biomarkers to

✓ Effectively design interventional clinical trial with optimal drug dose and schedule
✓ Identify compounds that are likely to fail at later stages of development
✓ Select lead drug candidates in discovery